"The acquisition of Relsys by Oracle strongly demonstrates Oracle's commitment to two major trends driving the industry today, namely the move towards a comprehensive connected eClinical approach to data management and the critical importance of monitoring drug safety both before and after drug approval. Relsys is expected to strengthen Oracle's capabilities by adding a market leading pharmacovigilance solution and new advanced drug safety analytics capabilities to the Oracle Health Sciences industry suite."
Alan Louie Ph.D.
Research Director, IDC Health Industry Insights |
